Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis

Ustekinumab, an inhibitor of the interleukin-12/23 pathway, received Food and Drug Administration (FDA) approval in 2019 for induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis (UC). Data regarding the efficacy of ustekinumab in the treatment of extraintestinal m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Kelly A., Shen, Jeanne, Rieger, Kerri, Wei, Mike T., Gubatan, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699508/
https://www.ncbi.nlm.nih.gov/pubmed/36447766
http://dx.doi.org/10.14309/crj.0000000000000881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699508/
https://www.ncbi.nlm.nih.gov/pubmed/36447766
http://dx.doi.org/10.14309/crj.0000000000000881

Ejemplares similares